0001193125-22-292007.txt : 20221123 0001193125-22-292007.hdr.sgml : 20221123 20221123160302 ACCESSION NUMBER: 0001193125-22-292007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20221118 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001797336 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823578375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39279 FILM NUMBER: 221416304 BUSINESS ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: (857) 444-0553 MAIL ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 8-K 1 d169360d8k.htm 8-K 8-K
false 0001797336 0001797336 2022-11-18 2022-11-18












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 18, 2022



Ayala Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)




Delaware   001-39279   82-3578375

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

Oppenheimer 4

Rehovot, Israel 7670104

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 444-0553

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange

on which registered

Common Stock, $0.01 par value per share   AYLA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 18, 2022, Ayala Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Requirement”).

The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market and the Company’s common stock will continue to trade under the symbol “AYLA”.

In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days, or until May 17, 2023, to regain compliance with the MVPHS Requirement. To regain compliance, the Company’s MVPHS must close at $5,000,000 or more for a minimum of 10 consecutive business days prior to May 17, 2023. In the event the Company does not regain compliance with the MVPHS Requirement prior to May 17, 2023, Nasdaq will notify the Company that its securities are subject to delisting, at which point the Company may appeal the delisting determination to a Nasdaq hearings panel.

The Company intends to actively monitor its MVPHS and may, if appropriate, consider implementing available options to regain compliance with the MVPHS Requirement. The Company may also choose to transfer the listing of its Common Stock to The Nasdaq Capital Market. However, there can be no assurance that the Company will be able to satisfy the Nasdaq Capital Market’s continued listing requirements, regain compliance with the MVPHS Requirement, or maintain compliance with the other listing requirements.


This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s intent or ability to transfer the listing of its common stock to the Nasdaq Capital Market, its intent or ability to regain compliance with the MVPHS Requirement, and its intent or ability to regain compliance with other Nasdaq listing requirements. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other important factors, including the risks that the Company may not be able to satisfy Nasdaq listing requirements, the Company may not be able regain compliance with the MVPHS Requirement by May 17, 2023 or in the future, Nasdaq may not grant the Company relief from delisting if necessary, and the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Ayala Pharmaceuticals, Inc.
Date: November 23, 2022     By:  

/s/ Roni Mamluk

      Roni Mamluk, Ph.D.
      Chief Executive Officer and President
EX-101.SCH 2 ayla-20221118.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 ayla-20221118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 ayla-20221118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 18, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001797336
Document Type 8-K
Document Period End Date Nov. 18, 2022
Entity Registrant Name Ayala Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39279
Entity Tax Identification Number 82-3578375
Entity Address, Address Line One Oppenheimer 4
Entity Address, City or Town Rehovot
Entity Address, Address Line Two Israel 7670104
Entity Address, Country IL
Entity Address, Postal Zip Code 7670104
City Area Code (857)
Local Phone Number 444-0553
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol AYLA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d169360d8k_htm.xml IDEA: XBRL DOCUMENT 0001797336 2022-11-18 2022-11-18 false 0001797336 8-K 2022-11-18 Ayala Pharmaceuticals, Inc. DE 001-39279 82-3578375 Oppenheimer 4 Rehovot Israel 7670104 IL 7670104 (857) 444-0553 false false false false Common Stock, $0.01 par value per share AYLA NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d169360d8k.htm ayla-20221118.xsd ayla-20221118_lab.xml ayla-20221118_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d169360d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d169360d8k.htm" ] }, "labelLink": { "local": [ "ayla-20221118_lab.xml" ] }, "presentationLink": { "local": [ "ayla-20221118_pre.xml" ] }, "schema": { "local": [ "ayla-20221118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ayla", "nsuri": "http://www.ayalapharma.com/20221118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d169360d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d169360d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ayalapharma.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-292007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-292007-xbrl.zip M4$L#!!0 ( &" =U4/47.H/P, %8+ 1 87EL82TR,#(R,3$Q."YX M?-)''V\K"==HK-!J'&5)&@&J0I="S<=18V-N M"R&BC\E-QA#EG&1F^9UX11 MGJ9Y^A9./L.G8$;!E:APB-7UTHCYPL$?Q6L(H%.M%$J)2S@3BJM"< E?>LIO MX%P5"9Q("1,/L\33HKG&,NFLWMHRM\4"*_[R!0 E3-ED,<\L:&2G%I(5&%-$ ^GO<%/Q4*4V\=F' :9$L8($5A:+9*ZO&0DV[7NY>#B.49H>,&H*1ZG& 40* M]>\.A!=/J3^&3NY!;@X"(#L\/&1!ND&I=.L1=-;?L588M+ES1DP;AV?:5*_%"%V%&=F34_XK[0L3^*LY&\4&6D+$(U(/$MU01 MV+.)]/5]$I%5<^Q-Q&YK8G^(_6&;]X=;_\D9V!QK'_^ACS][OU?\]];"?\!$ MJ\OGDAGLMJ?71'%1M*NK/>Y?ESODLWJS7PP^#^]V.M[<))W7X),KI5UP-&3" MZUJHF>ZNZ-(W<=YW\@1G$#98SDUAM,3=>X[51M=HG*!5?S<,K8&%P=DX\AL_ M[O?,#\FG">V97N6>@_7Q\F)&$)07=_1ZK!/.@R^\&+R@]>C@O9\KT@!_^#HYW_E$K-X(YOBM5KI: MMCQ/=='XEZC_/E'E)T7LEN?47 3VS"(0])A,2/W'7NHKGCW3$NEOG @=G*7^ M0__R>@O#(U6QA+3(P,C(Q,3$X7VQA8BYX;6S-G&UOVS80Q]\/Z'>X>6\V MH/)3BV$UFA:9DPS!TC9HW&W8,!2RQ-C$)-(@Y=K^]B/UT,@Q)5/FJ< MD;/>CLC>VS?/OGO]O>?!Q=7U>_!@F20K.1D,-IM-/[RG3/)HG2A)V0]X/ #/ M*^*GLT_P1U9N A])1'Q)(/9E0@3\NJ91.!D/Q^/1:/A+_^=RFB"^UH/03\@$ M1J/!^.5 1\)X,AQ.AB_A_!U0EY%T(M/S-SQ(7T.+!J$R0G_E%6&>/N6-QMZ+ M47\KP]X;73!_=?PYB6[4$:0>)H)'I*:POIQ6[^7QR6ZEXLDV(2PDN?)7;1[D M44M![C-5#5\J*4G07_ O@Y#0%!!]X.D#W>$/ZHO/4ZYX/Y_+1/A!LE\OTB\1 M%\7)U,19SY TV&](QYV+8$_+%T&AHPZ/^,\C!@%7W[=5XJ6*1?J]X+&QB[P< M-US\',TC8YN:)'6DQYLP[]/=,:^94-F8()*OA<*KR; M:C^55M42(LE-TW[=D#R/%>;J3W(5^0M;)!\E=82DN75NN.B"I$$(""J\)!KEY_VY(7_!@K>=FIKJW)7D_IR. C8WSPVLNN![J M(%%:"(-6=D83O\TRD9:]XF!X2P3EX24++]3/,TUY?)3<,9AF*[PF" -5@R V MLUD)4#5 %T'#MX76C1Q;]X^Q6?A(%E1ODEGRWH^MB3;G=KI5J##"JV/<-PHF M/=Q]PD,%T"60=@EM]&W8)%@WCP'R-0NX6'&1WBJY2]3@3/E:;5)V4QXVY/J( M5*>8V]GDUBGN0V ACSL3>P4AK0AY2= UD8;D&_@RS,SIYC"&Z(I&Y/TZGA/1 M;&+*>9V.A\$ -U]W!_^Q%B[E6ATR>22@L?LUT&O5- :H,W][':K-$KVGVALJ S/^YH8R, MFHV#4:#34:BSQ(\$NH] I2@N_KG^\^( ="7XP+#V,:W9,*!_@A=$]*?J\(.8 M\0T["?QR^E/ WF#'!/U#&!KRCR5; EZ7 2Y %\*%'=M '>IV+MI9X<>N*_SX M::!NM'1DA1^WL<*/O]T*/]OPUE9X)!O6*WRM%\P5/OM)^+3EOMV?9K!N(^@VUT>V2LX;WN@_S.@*RT@ W7WL_Q>HK2EM2*Y(V3KK?":(!=X M:P21",XKP'X)9XI;;+R,QV%> M5UN;*@/+Y]QZ M"_XHJ2-$S:USPT47. U"2&3FRI!).U/90J-E)&V[Q5DW+[?!4KDE33Z(8,[M M>/TT&N'5,1CKZ*$>]EI:5,#Y($)[?1O75,OF,9[O7<9$+-34_";X)EFJSB#<-#OL9>4$9@ MJ_[G8)+JNXG9I]D:\F_([Q;^:D.\/@X!^PI-9.:W\% F_P@B%O M&3#1;N.B M?.)&'>G?#)2?HMGOQU%G_@=02P,$% @ 8(!W53:^-AG4! [BT !4 M !A>6QA+3(P,C(Q,3$X7W!R92YX;6S5FF%OXC88Q]^?=-_!R]YLTD(([=U: M5.[$:'M":WL5<-NT-R>3/( UQX[L4.#;[W&"3P1"C_1N4]P7$!S_'__]_!PW M=G+U?IUP\@1*,REZ7MAJ>P1$)&,FYCUOJ7VJ(\8\HC,J8LJE@)ZW >V]?_?Z MU=4/OD^N;X++$MU-PA6JU4KGC&A)5]F&%*W(ID$Q/=M_<'D$_FC:*Y+ M1L"!:B )U1DH\MN2\;C;:7D?T]N\C""3%@"NUJ9;A2;+S+R4_0SR4774@C@'#;DE@DJ(D8Y&5O+OY"A MB%JDSSD9&9E&GQK4$\2M;53.Q#]=\S$U[LGK5P3_,)%"YZ4]SZ1CFXWU5/&6 M5'-TVSX+K,C;U:P/1*NS7!)>7EX&^=ER?C//5R$*OJ>A M/G8[-EV_Y71^JJ$]4=G0+KF^BDHAJ8IL.#P\P%8>_=L:04H5QO.C!4YT5CU3 M,JE,SK8U66E4JAA4S\/NXU7OD50QJ1 VEGADJ=&+3(UKRLTYF(%2$-\5W3[J M,K>(,ZB&O.9WQE.,Q@'V0%$^Q#&__ATVIV(Z(FXNKB.&+;8S9[#9^62":3R5 M5EG37$AEGY;-&^?8/ )ZQ>D^OL:[H[J0]L3-I[5GV&)[ZPRV8FX8P9R9CHKL M@28G4ZO6-A=:M5_+[%?'F.'"0*I4JCRU8\PP#.02I_C-0,8U$7XE5-.)?L6^ M!7SA&.!;QN%AF4Q!U:.YJVLZNEVOEM.E8YPF=#V,,0ULQHK%Z4N@'0W2=()' MC6]QGK4=P]F/8TRRWG[A(AG">B@K S0=8Z5IBS!T$^$ #S^JB5R)%P'RA>?:JOQP)':^]?KK. .P;-HB=&>%7AZ-Q5W8RRX^JW4$W!>_EMFYF\P> MIV2L>0L M8AD3\WN*C3!C[31F52 MA[KF)%-Y\K^[/5%S">T9M7CQ0^QF'2VHF$.= MQZK5VN;"JO9KF;FV#W*3@)KCV/N@Y"I;X/R>4E%S"^M(B.82?-:V!>G.5LBV M.VN<181FQESQFD9-BA7ZQB.L\&SY_0_;)5?!05[NL,"\IER<,1_FI5LL^1=0 M2P,$% @ 8(!W5;-($)JS$0 LV4 X !D,38Y,S8P9#AK+FAT;>T] M:W/B.+;?IVK^@XK9V2)5O RDDY#'5H;0W=Q)DUQ@=F;OEREABZ"-L3R2G(3] M]?<2F1X'>%J6<409@(H MQ21WDW%//@_N9X8]ULP@Y^3DI&SN)J +D.D"U4JE5L;; ZI8 DXG/IT!IQ/J MTW!$Y9B67#$VZ#N..V)C6N2!TC1PTV4B+5=8[6[""&2 <\K8)U #: _;+??NI>3\'UQX+['< Z5@-( $=XUC&&Y=C%GCP5W_TZ5V,Q)/NLB'\H MK47'*3K'OVN1N0>_C#D3!*# ENJWLWVS[,,FQ^,6"^= M/P2."B^]!,V6^HIJ=C'%+1DYO3?%U5L!F]Q)ETW7*<]0)Z7FE'KEK :605/A M(Z.O.*I(?7X7-%S8"Y.YV?N/W-.CQG'ID >G&5B?#?7IF,H['A3Q>X/02(OD M%\GO1O%/.%V83(9&LSABYB[XZ#"=0HNPD;D<"*W%V/PR$!)03WYQPB>BA,\] M\D/%_,E=_/T'YT/E]*P[1X#X3OG2YASR^==K]U17K]RWZKMQJ=RBNA MTVLU?^FV^^U6CUQVKDCKM^;GR\ZG%FG>?/G2[O7:-YVOPK&Z#QQ_O>Q];G<^ M]6\Z!7)5:I9(M7)8/YG#*[/H-I(Y*Q";-&JI9'YXEF26*@ V*YRG5DNKSH^+ MN]]22Z>;28S$,H8YKR55'V^Z7\B9"FF0&J(1UZP(O[@,G.>CI"$XDU51Q)5P M(PPB,I',]I[:1$FS+OJLC*AF3;NOVIMM_>YMS&TD5 MT4 3+4B/N2ASQ*D1(8ESF/<.WAY!,21ZQ!"W2'+-87SKR1W1X(Z12U<3N.V< MU.JK\7PUSF+D@^AT62BD)OGDND4A\F%*D]8#0,:WF7?06)U=)';AUH1/+1M5 M[6H@B,WVSG.0(38\F& ,PT<>G4P8A1@V=]$1#VP\@!#3.2X0'+AH3M[MR/[M M2+6^#VE;*3LV#>RR.ZXPY]<=N+.S;[G$P@NY-947ET6:NY"Q%D@[<$L;A&0W M"U'9!RGRK2<*E@ W:O4OV3JABO1"YF(NY!$>D+96I F;@F'SENU=N%<(]]<0 M!BLZ=. SXC+?QYC(U#DK.7,=4L]+KN.UXKVZPO=IJ%@C^;)>1C("A4&=I893 MJ?P8TZY1B=%L5))<#Q&3]L.;32%K]1\Q^]?>W-T')HT6Q-2U&UX*&<]3W6&> M!.?E0^8GA']BW&4"$M([5AQ(1N^QVLD]UJ / B1D:\(YAG6SZY*,-)$9<6H8 M02)S>P&9 RSP?"\]FXT6V!@A 3_:.Q33X/3:HHHT'+2%-Y7.4 LD6(I0[-0 MB@=<%CW@%?/I(SC#E7'TMF*0R/P"_(O0\-GYAB7R1^XSN >>_QG50:=8.ZD> MG:RDV+=,N#Y]:L>U-==0ZIE4/*X6:X='Q[6CPRW(^!+:?KPG97^NW]]+[ITW M]@$SE1M($"3Y'\@/E,=-"K-34.*\ '(0A\S8L@/K6]]&+=Z634TQ'G.E_@Q< M0179/=[23(VN(9+ MSY-,J?CC&L)\9V>WA)[? M>6%UG605[:L[K[WEYFPP^M6!J&OG2<+0MI*4^9O.@U?@="L@K/7_CX?/"9$O MCCX<59S*$FG;G_3MQVC%N\4$_U;RP.4A]4GKB;F1Y@^,W S!A#!U0/) "8*D M6%.Z?#6C,2U%_/V'XZIS=*I(G_DL'(D@\4.FJ.)'F F32PCI#.YK2H.H7PCW M+&[GCP^/#A;E[-EA\;4 QW:+NWEF)%ROUXN5P\/:=@<9N[%P/W+W$507[+$M M+DD27\;26"!\B 6EX(YYI =2R<@U54F-][W$]#+G,)M4,W?1'#'WWAP;T!#R M_5!RS!0&XHD,F"\>D6MX$YFY6?K-.9L11S+D/NHI5X1CTY$'7->"*#Z.?$T# M)B+E3X@"H5?#B5DA'B &0"\;X,3'&7):I(Q@'DEH,$GN#84/2.(XK%5PC)Q5 M8Z4L?7AV46Y?13=GV@#1J&3*;XMEOKDRX'9I[7RF:A>H_WBZM *PRE3]*KD& MEF$R$@5QM*F^VI$/A/ '%-BE0;B0RB=']?KIHC7;E&;,9P5DEJ/DJ[W57$], M[B*F!Q @2Q 29HX#NQ$(2;UZ&$OHW"D<'K[EG2/2_-@EU5JE!(";(_=WL=U1 M;'M@A5T@>'#W!4P8V#'_+RRS4V+ U)8:BP*[T9X[=5ITJHE)G\KVS+%R(MD; M9ZO6*R4[XT$F:'E7@GTJP:UD:+>Q[])TRZ#GE1#Q[QYP?D/*L%$R@6I%-T.V M1.(W6?PM%,@K5O.#@_VJD)WS78E>28G:2D5,OJO2&ZM2C17K>7>_JA3/N;4J M[3W]RD2)-L]A$C*E<%FG&>I\DO? 3E>G.>_-!]]N\\%SCB.WJ%FLV.T2M7G3 M$Y ^/NB$.L"H.R*N3Y5ZK;.IYQ+QK2DF*2KOV4"2\D5O,@:XO'JU [U7(-I+ M5#*3]C@C92SV+F]^_ <^ !02,)HZBEE_]:WU.<6^<>)4!T;Q=RZ98Q '5.MI MX=X7R-\JI8I#0BK) _4C1D)\8FSTW]?2M(IT]2Z$[&@&DD/(/D1@':H\^@?YY L(Y,D7*N_9PG'L0F_2:T24[<##*)N1 MP82XIK@/,]Z#Z6"F]6>NHLX5 1I#I(Z+WI$[*1[U"(/U$*OL5!&/#7E@6X)M MD;-R2!:?,Y@^7E C>92"HU-;Z4R@81U@1HC=Q'@VM&7(7QT4T^K3=@\WI*MO M%_\O+)#!L_2RIZ*YB]8*JF\XS$Z&?3*CFG;0BZ2D'Y:DI"]+DO9PC3@60 B7 MRC9?."@:@>0R'S(GD-Q F#PJ4LQ 8WBXRA\S)^;W,H^>XLT,6OY$US\D- 'VC@8D&5NJ8[ 8'Q@7^/2D_9@RAO>1)G[:-3R],TD\L* M<6DCZY_Z*=+V@9=7*T7L[WCV6WMVV)[1QB>UWW\'?F^I?K#Q@GK@3YDP;<" M.1"F^8]THC $ALGQA0]I2 =IMI"-'T[,G]-D0^'33!VM'".Q_A1\OP^$?__= M0J7PIYON5:M;;-Y<7U_>]EJ-Y,N?NU+H.$M+A<1\!4%:K($MQB5MS<96.D#6 MG-*2("H[VUM5]M9E'':;'0$(F3SHBOE@6,WIO"0?*?'L![L6$\)<9T#2$$@1ECJ!+9I>+V81\>Y@8;)^W#?+$UCI_H*Y U M3W*1/-IJ[$RJ5DYCEVNNG-,#< PNXP^P]\?XH#BPE,N.L<1,APRE&)-,&&E2 ME#B*)-?730QC[#AS/QT7.T DL!Y1;3Q(C Z&Z6%6I%(8+ZBJNS3.%2=P_RM8/\U4%A1MR1Z#2)W##Z/ZX0 M4%B&UH9XX$$+2' ,SY!JDUC9CXRRUPI(#H@7Z0H]69"K$NDO&5!8R@0[>!PI M35Q?0-@)BII1&: Q--1)W4$%NJ:1/\N6UVS5"%ADA$M-'-Q\U:RH#%*7*-BIVD:V!*BHL&_ M42-@4B]Q)@6DBZUHA8+/83ZF$VQ(8R#R^',Z"+Y!_ )$LRUB,!]- M_H1,P*W2!W"U)J82H3TUVUUHYTGJ*P&9DT"IM ;!NN09,S4T*&>+9PB;L>-- M&G*=&J,2^2P>0?:DT09@M@O1T8"A1:1*04:"2"YX*R-! &7VAYV!F5; I>R^R_2 MN>FW2+?UZ;)[U>Y\(A]ONK_"U^+US&W>)?2EU>GW&FO0W$M$U<>B23.2 M,(E^!"PH-XR-$C$5?B/LXM]:6Y(8MW%J[,:-!QI7>2OZ KC=3 M'[J&C[B5M(NIU7A:*#HY+)%+$,#,U/'RMM2E][0G(_:>B&VPCPB"K$,"#D;, M-.C#.F C,-(D0WPR7XU$!!$8*$9B$VQLM8(@6!*)6^(+X#"T694 -A5RENP8 OG7\W547SN>M45GUC MO)9K<7\)-8 5$6P HN#(URH-MS10UE+ ^%HD G++X]@5DC;:@>TW\;T>&>.FV&T74(B+MF+_&Z MV5S#"E#'SN'!:19T^03L;_)BD1]-[$P\3+P*C 4*6>=@ *\0AOOK' M\':-@B[ZB9AJI*^1+<2BG%@.3)<-RFC/C%EC3R&$R+8_JI04_S*U M15-D^^L6&-_T@^U/GLO]+M]5[\;0B^Y8Q>ZJ1,3W;'8(5EAV'>!&HH$LC M/,+(BBTL X9;P6[AAK"B.& CZ@_1-N-$1G=B SP(:<6=CI@S@BBE_\P;R$8 MSNRY^M+M:/NI-2_I1T/!BVO;,BERS_>6'B;M7O/WG]U!5M]IQG6M:/M'[7"F MN6U*G1?M.ME^W[OV);SVS. ]4*"#\UQMXSG"VA>+K7WI28::B\1,#MRJ>&L) MXMG[4W2K+PS[6@U,*]B(+PULI <#!"M=]BU__ST29DZ,?IHT7@[GW;K?-IR@ M[N@5RZH,7P,.R<+8C^Y?O?'MVS%!+SASAD$%,%REJ]([C_YL,S='F*_.OPU" MFBSJ%K(7\T;\K(=/SV279"-G9?N_19C_2^+B_P%02P$"% ,4 " !@@'=5 M#U%SJ#\# !6"P $0 @ $ 87EL82TR,#(R,3$Q."YX M&UL4$L! A0#% @ 8(!W53:^-AG4 M! [BT !4 ( !0PH &%Y;&$M,C R,C$Q,3A?<')E+GAM M;%!+ 0(4 Q0 ( &" =U6S2!":LQ$ +-E . " 4H/ F !D,38Y,S8P9#AK+FAT;5!+!08 ! $ $! I(0 ! end